Tagged with B

Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange.  She joined…

Brazil Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in January 2025, she has focused on navigating the rapidly transforming skincare landscape, balancing traditional physician relationships with emerging digital channels,…

Taiwan PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren Wang outlines how ONIVYDE® provides the stability to advance a more ambitious pipeline, how a virtual model sharpens scientific focus…

USA Matt Shaulis, General Manager for North America at BeOne Medicines, discusses the company’s rapid rise as a global oncology leader and its growing impact in the US. He explains how BeOne’s fully integrated research, development, and manufacturing model is transforming the way new cancer therapies are discovered and delivered. Shaulis…

USA Spiro Gavaris, President of Lupin’s US generics business, shares a candid assessment of the shifting dynamics shaping today’s generic and biosimilar landscape. He outlines how Lupin is positioning itself for long-term leadership through focused investment in complex generics across inhalation technologies, injectables, and biosimilars, while navigating a market challenged by…

France Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health institutions. Drawing on extensive oncology expertise and a deep commitment to national competitiveness, he champions a unique model in which…

Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…

USA Lonza’s transformation under the One Lonza Strategy comes at a moment of significant change for the global biologics and CDMO sectors. Gordon Bates, Head of Integrated Biologics, reflects on the rationale behind the company’s new organisational model, and how a more unified structure is designed to accelerate decision-making and strengthen…

France Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on the scientific foundations of RNAi, the strengths and pressures of the French rare-disease ecosystem, and the conditions needed to ensure…

Taiwan Yenchen Huang, Head of Investment, VP at Diamond Biofund, one of Taiwan’s pioneering evergreen venture capital funds focused on life sciences, our interviewee brings a unique perspective combining scientific training with financial expertise. Since joining the fund in 2014, shortly after its 2013 establishment, Huang has helped guide early-stage biotechnology…

Taiwan Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep understanding of cross-cultural business dynamics and healthcare system transformation. Since assuming his current role, he has spearheaded an ambitious organisational…

USA Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the launch of a new 2030 strategy and revised mission aimed at integrating HEOR into everyday health policy decision-making. This includes…